Drugs / VMD-3866
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07072468 | Dec 2025 → Jun 2027 expected | chemotherapy-induced neuropathy | VM Therapeutics LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VMD-3866 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07072468 ↗ |
| Action | Inhibit | “The study medicine will work by selectively blocking a specific sub-type of proteins (called T-type calcium channels) in the nerves under the skin which will lower the activity...” NCT07072468 ↗ |
| Route | Topical | “It is a topical gel, meaning that it is applied to the skin” NCT07072468 ↗ |